Zymeworks (ZYME) Stock Forecast & Price Target

Compare

546 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZYME Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Zymeworks

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZYME Stock 12 Month Forecast

Average Price Target

$25.50

▲(42.46% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $25.50 with a high forecast of $32.00 and a low forecast of $15.00. The average price target represents a 42.46% change from the last price of $17.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","33":"$33","15.75":"$15.75","21.5":"$21.5","27.25":"$27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,15.75,21.5,27.25,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.08,20.07384615384615,21.067692307692305,22.06153846153846,23.055384615384614,24.049230769230768,25.04307692307692,26.036923076923074,27.03076923076923,28.024615384615384,29.018461538461537,30.012307692307694,31.006153846153843,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.08,19.57384615384615,20.067692307692305,20.56153846153846,21.055384615384614,21.549230769230768,22.04307692307692,22.536923076923078,23.03076923076923,23.524615384615384,24.018461538461537,24.512307692307694,25.006153846153847,{"y":25.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.08,18.766153846153845,18.45230769230769,18.138461538461538,17.824615384615385,17.51076923076923,17.196923076923078,16.88307692307692,16.569230769230767,16.255384615384614,15.94153846153846,15.627692307692307,15.313846153846153,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.57,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$32.00

Average Price Target$25.50

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

11/06/25

Zymeworks' Strong Q3 Performance and Promising Pipeline Drive Buy Rating

Charles Zhu

LifeSci Capital

$32

Buy

78.77%

Upside

Reiterated

11/06/25

Zymeworks: Promising Advancements and Financial Stability Support Buy Rating

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

10/27/25

Zymeworks' Promising FRa ADC Potential: Buy Rating Affirmed by Analyst

Eva Fortea Verdejo

Wells Fargo

$14→$15

Hold

-16.20%

Downside

Initiated

10/24/25

Zymeworks assumed with an Equal Weigh at Wells FargoZymeworks assumed with an Equal Weigh at Wells Fargo

David Martin PhD

Bloom Burton

$19.5→$27

Buy

50.84%

Upside

Reiterated

10/24/25

Zymeworks' ZW191: Promising Efficacy and Safety in PROC with Potential Market Leadership

Stephen Willey

Stifel Nicolaus

$28

Buy

56.42%

Upside

Reiterated

10/24/25

Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME) and Inspire Medical Systems (NYSE: INSP)

Robert Burns

H.C. Wainwright

$26

Buy

45.25%

Upside

Reiterated

10/24/25

Zymeworks data for ZW191 'highly encouraging,' says H.C. WainwrightZymeworks data for ZW191 'highly encouraging,' says H.C. Wainwright

Yigal Nochomovitz

Citi

$22

Buy

22.91%

Upside

Reiterated

10/23/25

Promising Early-Stage Data and Strategic Initiatives Drive Buy Rating for Zymeworks' ZW191 Program

Mayank Mamtani

B. Riley Securities

$30

Buy

67.60%

Upside

Initiated

10/10/25

Zymeworks initiated with a Buy at B. RileyZymeworks initiated with a Buy at B. Riley

Andrew Berens

Leerink Partners

$30→$24

Buy

34.08%

Upside

Reiterated

09/04/25

Strategic Shift to Zanidatamab Drives Optimistic Buy Rating for Zymeworks

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$24→$30

Buy

67.60%

Upside

Reiterated

03/14/25

Jonathan Miller

Evercore ISI

$12

Buy

-32.96%

Downside

Reiterated

03/06/25

Zymeworks (ZYME) Gets a Buy from Evercore ISI

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

11/06/25

Zymeworks' Strong Q3 Performance and Promising Pipeline Drive Buy Rating

Charles Zhu

LifeSci Capital

$32

Buy

78.77%

Upside

Reiterated

11/06/25

Zymeworks: Promising Advancements and Financial Stability Support Buy Rating

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

10/27/25

Zymeworks' Promising FRa ADC Potential: Buy Rating Affirmed by Analyst

Eva Fortea Verdejo

Wells Fargo

$14→$15

Hold

-16.20%

Downside

Initiated

10/24/25

Zymeworks assumed with an Equal Weigh at Wells FargoZymeworks assumed with an Equal Weigh at Wells Fargo

David Martin PhD

Bloom Burton

$19.5→$27

Buy

50.84%

Upside

Reiterated

10/24/25

Zymeworks' ZW191: Promising Efficacy and Safety in PROC with Potential Market Leadership

Stephen Willey

Stifel Nicolaus

$28

Buy

56.42%

Upside

Reiterated

10/24/25

Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME) and Inspire Medical Systems (NYSE: INSP)

Robert Burns

H.C. Wainwright

$26

Buy

45.25%

Upside

Reiterated

10/24/25

Zymeworks data for ZW191 'highly encouraging,' says H.C. WainwrightZymeworks data for ZW191 'highly encouraging,' says H.C. Wainwright

Yigal Nochomovitz

Citi

$22

Buy

22.91%

Upside

Reiterated

10/23/25

Promising Early-Stage Data and Strategic Initiatives Drive Buy Rating for Zymeworks' ZW191 Program

Mayank Mamtani

B. Riley Securities

$30

Buy

67.60%

Upside

Initiated

10/10/25

Zymeworks initiated with a Buy at B. RileyZymeworks initiated with a Buy at B. Riley

Andrew Berens

Leerink Partners

$30→$24

Buy

34.08%

Upside

Reiterated

09/04/25

Strategic Shift to Zanidatamab Drives Optimistic Buy Rating for Zymeworks

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$24→$30

Buy

67.60%

Upside

Reiterated

03/14/25

Jonathan Miller

Evercore ISI

$12

Buy

-32.96%

Downside

Reiterated

03/06/25

Zymeworks (ZYME) Gets a Buy from Evercore ISI

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zymeworks

1 Month

xxx

Success Rate

7/9 ratings generated profit

Average Return

+8.66%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 77.78% of your transactions generating a profit, with an average return of +8.66% per trade.

3 Months

xxx

Success Rate

8/9 ratings generated profit

Average Return

+19.10%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +19.10% per trade.

1 Year

Charles ZhuLifeSci Capital

Success Rate

9/9 ratings generated profit

Average Return

+41.39%

reiterated a buy rating 2 days ago

Copying Charles Zhu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +41.39% per trade.

2 Years

xxx

Success Rate

9/9 ratings generated profit

Average Return

+47.71%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +47.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZYME Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZYME has received 19 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ZYME average Analyst price target in the past 3 months is 25.50.

Each month's total comprises the sum of three months' worth of ratings.

ZYME Financial Forecast

ZYME Earnings Forecast

Next quarter’s earnings estimate for ZYME is -$0.51 with a range of -$0.86 to -$0.34. The previous quarter’s EPS was -$0.26. ZYME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ZYME has Preformed in-line its overall industry.

ZYME Sales Forecast

Next quarter’s sales forecast for ZYME is $35.45M with a range of -$8.00M to $93.60M. The previous quarter’s sales results were $27.60M. ZYME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ZYME has Preformed in-line its overall industry.

ZYME Stock Forecast FAQ

What is ZYME’s average 12-month price target, according to analysts?

Based on analyst ratings, Zymeworks Inc’s 12-month average price target is 25.50.

What is ZYME’s upside potential, based on the analysts’ average price target?

Zymeworks Inc has 42.46% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZYME a Buy, Sell or Hold?

Zymeworks Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Zymeworks Inc’s price target?

The average price target for Zymeworks Inc is 25.50. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $32.00 ,the lowest forecast is $15.00. The average price target represents 42.46% Increase from the current price of $17.9.

What do analysts say about Zymeworks Inc?

Zymeworks Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of ZYME?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Zymeworks (ZYME) Stock Forecast & Price Target

ZYME Analyst Ratings

ZYME Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zymeworks

ZYME Analyst Recommendation Trends

ZYME Financial Forecast

ZYME Earnings Forecast

ZYME Sales Forecast

ZYME Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts